Latest news

Mar 22, 20222 min read

CONNECT seminar om Nukleærmedisin

Nukleærmedisin med presisjonsdiagnostikk og persontilpasset behandling. Nukleærmedisin omfatter både diagnostikk og behandling ved bruk...

Dec 10, 20211 min read

GSK is CONNECT's 6th new partner in 2021, and sponsor of the Cancer Crosslinks 2022

CONNECT’s newest partner, GSK, sponsors the Cancer Crosslinks 2022, and is increasing its focus on oncology and hematology. These are...

Dec 8, 20212 min read

CONNECT Seminar on Clinical Decision Support Systems

Clinical Decision Support Systems: useful for what and for whom? In his introduction, Eivind Hovig, Professor at the Centre for...

Oct 20, 20212 min read

CONNECT's partner, Eli Lilly & Company, is now part of the IMPRESS study

CONNECTs partner Eli Lilly & Company is now offering participants of the IMPRESS study a new and promising medicine.

Oct 13, 20212 min read

CONNECT seminar: The new EU regulations on IVDR – how to be prepared?

Sep 16, 20211 min read

The winner of King Olav V’s Prize for Cancer Research 2021 is Bjørn Tore Gjertsen

This year’s King Olav V’s Prize for Cancer Research will go to Professor Bjørn Tore Gjertsen, one of CONNECT’s Steering Committee...

Aug 30, 20213 min read

Opinion piece (only available in Norwegian): Nye kreftbehandlinger krever nye samarbeidsformer

Norge står i en internasjonal særstilling for å kunne samarbeide godt i helsesektoren, men det krever at politikerne tør å satse, skriver...

Aug 30, 20211 min read

CONNECT at Arendalsuka

Connect had the pleasure of participating at Arendalsuka. Here you can find the debates and conversations we had during the event....

Jul 11, 20212 min read

Novartis enters IMPRESS

One of the largest pharmaceutical companies enters the precision cancer study IMPRESS in Norway.